Advertisements

Флюкостат

Quick links to important sections

Флюкостат

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Флюкостат

What is Flucostat?

Flucostat is a pharmaceutical medication classified as an antifungal agent. It belongs to the triazole class of compounds and is primarily used to treat and manage various fungal infections. The active ingredient in Flucostat is fluconazole, a systemic antifungal that works by interfering with the synthesis of ergosterol, a vital component of fungal cell membranes.

Mechanism of Action

The primary function of Flucostat is to inhibit the fungal enzyme cytochrome P450 14α-demethylase. By blocking this enzyme, the medication prevents the conversion of lanosterol into ergosterol. The resulting deficiency in ergosterol leads to structural damage in the fungal cell wall, increasing its permeability and ultimately inhibiting the growth and replication of the fungi.

Applications

Flucostat is used in various clinical scenarios to address infections caused by different types of fungi, most notably those from the Candida and Cryptococcus genera. Its use cases generally fall into the following categories:

  • Yeast Infections: Often used for mucosal candidiasis, including oral thrush and esophageal infections.
  • Systemic Infections: Employed in the treatment of generalized candidiasis affecting internal organs.
  • Cryptococcal Meningitis: Used to manage infections caused by the Cryptococcus fungus, particularly in individuals with compromised immune systems.
  • Prophylaxis: Utilized in certain medical contexts to prevent fungal infections in patients who are at high risk due to chemotherapy, radiation therapy, or other immunodeficiency factors.

Pharmacological Properties

Flucostat is characterized by its high bioavailability and its ability to penetrate various body fluids and tissues effectively. After administration, it reaches significant concentrations in the blood, cerebrospinal fluid, and skin. It is primarily excreted through the kidneys, with a substantial portion of the active substance remaining unchanged.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus
Advertisements

What side effects are possible with Флюкостат?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of this medicine (fluconazole) based on the frequency and severity of reported adverse reactions across various body systems. The table below summarizes the key categories of documented side effects.

Frequency Classification Examples of System Organ Class Reactions
Common (≥1%) Headache; Gastrointestinal symptoms (abdominal pain, diarrhea, nausea, vomiting); Rash; Increased liver enzyme levels.
Uncommon (0.1%–1%) Decreased appetite, constipation, flatulence; Seizures, dizziness, taste perversion; Fatigue, insomnia; Anemia; Vertigo; Cholestasis.
Rare (<0.1%) Serious Hepatotoxicity (including liver failure, sometimes fatal); Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis); Cardiac disorders (QT prolongation, Torsade de pointes); Anaphylaxis; Blood disorders (leukopenia, thrombocytopenia).

Serious Safety Restrictions and Precautions

The regulatory profile highlights several critical safety considerations:

  • Contraindicated Medications: Co-administration is strictly contraindicated with specific drugs (e.g., cisapride, pimozide, quinidine, high-dose terfenadine, erythromycin) due to a heightened risk of serious or fatal cardiac arrhythmias (QT prolongation).
  • Hepatobiliary Risk: Rare but serious hepatic toxicity, including liver failure, has been reported. Careful monitoring of liver function is specified, and discontinuation is required if signs of significant liver injury are observed.
  • Cardiovascular Risk: The medicine has been associated with QT interval prolongation and Torsade de pointes, especially in patients with pre-existing heart conditions, electrolyte disturbances, or those concurrently taking other QT-prolonging agents.
  • Pregnancy and Dose: Prolonged use of high doses during the first trimester of pregnancy has been associated with congenital abnormalities in infants. Its use during pregnancy is therefore limited to situations where the potential benefit is judged to outweigh the potential fetal risk.
  • Population Specificity: Dosage adjustments are officially required for patients with renal impairment due to the drug’s primary elimination pathway. The oral suspension formulation may contain sucrose, which is relevant for patients with hereditary fructose or glucose/galactose malabsorption.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the potential for serious toxicity following an overdose of Флюкостат (fluconazole). Acute overdose reports are officially documented to include central nervous system (CNS) manifestations, specifically hallucination and paranoid behavior.

Overdose-related risks are high for the cardiovascular system, with a potential for dangerous heart rhythm disturbances such as QT prolongation and the life-threatening arrhythmia Torsades de Pointes.

When to Seek Immediate Medical Attention

The regulatory guidance states that an individual must seek immediate medical attention for any suspected overdose. Emergency services should be immediately called if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose Management Focus Official Regulatory Statement
Antidote Status No specific antidote is known; symptomatic treatment is mandated.
Supportive Measures Supportive measures and symptomatic treatment should be instituted, with gastric lavage used if clinically indicated.
Elimination Procedure Hemodialysis is documented to decrease high plasma concentrations by approximately 50% and may be employed.
Special Considerations Overdose risk is amplified in patients with impaired renal function due to reduced drug clearance and prolonged half-life.

This structure ensures immediate medical attention is prioritized based on the documented severity of CNS and cardiac risks.

Advertisements

Therapeutic Uses of Флюкостат

Quick Facts: Therapeutic Applications

  • Relief from symptoms associated with yeast infections (vaginal candidiasis).
  • Management of fungal infections in the mouth and throat (oropharyngeal and esophageal candidiasis).
  • Use in a therapeutic plan for systemic fungal infections, including those affecting the urinary tract.
  • Supportive care to reduce the chance of fungal infections in high-risk patients, such as those undergoing specific cancer treatments.

What Флюкостат Treats: Main Uses and Benefits

Флюкостат (Fluconazole) is an established medication utilized for the management of infections caused by fungi. This treatment is indicated for several common and serious fungal afflictions, helping to resolve the underlying condition and alleviate associated discomfort.

The medication is frequently used to treat vaginal candidiasis (yeast infections), offering a focused therapeutic approach. It is also an important option for managing mucosal infections, such as those affecting the mouth and throat (oropharyngeal and esophageal candidiasis).

Beyond localized issues, Флюкостат plays a role in the therapeutic plan for systemic infections, including candidiasis that may affect the urinary tract or blood. Furthermore, it can be administered as a preventive measure to reduce the incidence of candidiasis in certain individuals who are at increased risk due to weakened immune function, such as patients undergoing bone marrow transplantation or chemotherapy.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Флюкостат?

The eligibility for Флюкостат (Fluconazole) is strictly defined by regulatory authorities based on patient profile and concurrent conditions.


Eligibility Scope

Classification Populations and Conditions
Populations for whom use is allowed Adults and children (typically 6 months and older) for established fungal infections.
Populations for whom use is not recommended Pregnant women (especially high-dose or prolonged use); breastfeeding mothers (for repeated or high doses); children under 16 for vaginal candidiasis.
Populations for whom use is contraindicated Patients with known hypersensitivity to fluconazole, related azoles, or excipients. Patients taking specific QT-prolonging medicines metabolized by CYP3A4.

Condition-Specific Eligibility Rules

Condition Eligibility Status
Renal Impairment Requires conditional use with dose adjustment for multiple-dose therapy.
Hepatic Impairment Requires caution and close monitoring of liver function.
Cardiovascular Issues Requires caution in patients with conditions predisposing to cardiac arrhythmias (e.g., QT prolongation, electrolyte imbalances).

Connection to the overall eligibility profile

Regulatory documents establish absolute contraindications based on hypersensitivity and the risk of serious drug-drug interactions, particularly those affecting the cardiac rhythm. Eligibility is further governed by placing limitations on use in specific age groups, during pregnancy and lactation, and by requiring conditional use criteria for patients with impaired organ function (renal and hepatic), as documented in official labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Fluconazole, the active ingredient in Флюкостат, is defined by its role as a documented potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4 in the liver. This inhibitory action is the basis for most pharmacokinetic interactions and exposure changes documented in regulatory sources.

Formal Contraindicated Combinations

Co-administration is formally contraindicated with specific medicines due to the risk of increased plasma concentrations and potential for QT prolongation and torsades de pointes. This includes the prohibition of combining Fluconazole with Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin. The combination with Terfenadine is also restricted when Fluconazole is used at multiple doses of 400 mg per day or higher.

Documented Exposure Modification

Fluconazole increases the systemic exposure of several co-administered drugs that are metabolized by these enzymes, including Warfarin, Carbamazepine, Phenytoin, and Oral Contraceptives. Conversely, some agents also alter Fluconazole levels: Rifampicin is documented to decrease Fluconazole exposure, while diuretics like Hydrochlorothiazide are documented to increase Fluconazole exposure by reducing renal clearance. Fluconazole absorption is unaffected by food.

Advertisements

Mechanism of Action

Targeting the Fungal Cell's Structural Foundation

Флюкостат (Fluconazole) works by intervening directly in the fungal cell's ergosterol biosynthesis pathway. The drug acts as a selective inhibitor of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This inhibition prevents the conversion of lanosterol into essential ergosterol, the primary sterol component required for maintaining the stability and function of the fungal cell membrane.


Causing Fungal Membrane Collapse and Dysfunction

By blocking ergosterol synthesis, the drug initiates a dual cellular consequence: the depletion of ergosterol and the simultaneous accumulation of toxic, partially formed building blocks (14-alpha-methylated sterols). These abnormal sterols integrate into the membrane, severely compromising its fluidity, permeability, and structural integrity. This targeted cellular damage inhibits the fungal organism's growth and replication (fungistatic action), which is the resulting physiological consequence of the mechanism.


Constraints on Mechanism Efficacy

The mechanism is functionally limited by specific biological factors in resistant fungal strains. These limitations include genetic mutations in the CYP51 target gene that reduce the drug's binding affinity, or the overexpression of efflux pumps by the fungus. These pumps actively reduce the intracellular concentration of fluconazole, altering its target engagement kinetics, thereby preventing the mechanism from achieving full inhibitory effect.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Fluconazole is administered through two official pathways: oral (using tablets, capsules, or reconstituted suspension) and intravenous (IV) solution. Because the oral form has high bioavailability, the same daily dose is typically maintained when a patient switches between the IV and oral routes.

Dosing is indication-specific. For many multi-dose regimens, a loading dose of twice the usual daily maintenance dose is administered on Day 1 as a procedural instruction to achieve necessary therapeutic concentrations quickly. Maintenance doses generally range from 50 mg to 400 mg once daily, though doses up to 800 mg daily are prescribed for severe systemic infections. A single 150 mg dose is the standard regimen for acute vaginal candidiasis.

Administration is typically scheduled once daily, although long-term or intermittent use patterns, such as once weekly maintenance for prophylaxis, are also officially labeled. Oral forms may be taken with or without food. For the IV route, the solution must be administered as a slow infusion, with the rate restricted to no more than 10 mL/minute.

Official guidelines mandate dose adjustments for specific populations. For patients with renal impairment, the dose must be reduced by 50% for multi-dose regimens when creatinine clearance is le 50 mL/min. Furthermore, pediatric dosing is calculated on a mg/kg basis, and special scheduling (e.g., every 72 hours) is required for neonates to accommodate their differing clearance rates.

Advertisements

Recent Clinical Evidence

Evidence for Use in Treating Yeast and Mucosal Infections

The research for Флюкостат in treating fungal infections, such as vaginal and oral candidiasis, primarily uses short-term Randomized Controlled Trials (RCTs) to evaluate patient-reported discomfort and mycological endpoints (fungal status). Studies examining recurrent vaginal candidiasis (RVVC) have explored long-term patterns where maintenance protocols were the subject of investigation over extended periods. Findings describe group patterns related to clinical status, but the status of outcomes after maintenance is discontinued remains an area of ongoing research.


Evidence for Use in Systemic Infections and Prevention

For severe fungal issues like systemic candidiasis, research includes observational studies and comparative RCTs that examine outcomes related to systemic or functional imbalance, such as mycological status in the bloodstream and patient survival. Studies report how outcomes evolved in patient groups, noting that results were observed to vary depending on the patient's underlying health status. For high-risk patients, such as those undergoing bone marrow transplantation, research has explored the drug's use as a preventive measure (prophylaxis) to measure the incidence rate of fungal infection during vulnerable periods.


Research Gaps and Uncertainty

Ongoing research addresses the risk of fungal resistance, which impacts the measured outcomes seen in clinical studies. Certain non-albicans species, notably Candida glabrata and Candida krusei, have demonstrated reduced susceptibility to the drug. Comparative evidence in some complex scenarios, like those involving low-dose prophylaxis or certain pediatric patients, is still emerging or limited. Overall, long-term effects are not fully established for all indications, and research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis
  2. Fluconazole - StatPearls - NCBI Bookshelf
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Флюкостат (FAQ)

Q: Why is Флюкостат sometimes given as just one pill?

A: A single-dose regimen of fluconazole is officially described for treating acute vulvovaginal candidiasis. This approach is described as feasible because the medicine is absorbed well and the active substance stays in the body for an extended time. This allows the active substance to quickly reach and maintain the necessary concentrations described as therapeutic.

Q: What kind of stomach issues are typically seen with Флюкостат?

A: Regulatory documents indicate that gastrointestinal issues are among the most common documented side effects. These reactions generally include abdominal pain, nausea, vomiting, and diarrhea. These symptoms are generally reported in official documents.

Q: Can children use Флюкостат?

A: Official information confirms that fluconazole is indicated for use in children from 6 months of age and older for certain fungal conditions. However, specific eligibility restrictions apply, such as the use of the drug in children under 16 for vulvovaginal candidiasis, which is generally not recommended and requires special consideration.

Q: Is it true that Флюкостат can cause headaches?

A: Yes, headache is one of the most common side effects of fluconazole documented in official regulatory and product information. This information is classified in the official safety profile of the drug.

Q: Why might a doctor prescribe Флюкостат for a long period?

A: The drug is officially prescribed for extended periods in specific circumstances, particularly as maintenance therapy. This long-term use is typically to prevent certain fungal infections from recurring, or for use as prophylaxis (prevention) in patients who are at high risk, such as those with weakened immune systems.

Q: Is it necessary to finish the entire course of Флюкостат even if symptoms improve?

A: Official information emphasizes that for full courses of treatment, it is important to continue taking the medication for the entire prescribed duration. Continuing the course, even if symptoms begin to ease, is a measure officially described to help address the risk of the infection returning.

Q: Does Флюкостат interact with alcohol?

A: A formal drug-alcohol contraindication is not always listed in regulatory documents. Due to the drug’s potential for rare but serious hepatic side effects, regulatory information advises caution regarding alcohol use, especially for those with existing liver risk factors.

Q: Is Флюкостат effective against all types of yeast infections?

A: Fluconazole is effective against a broad range of fungal species. However, official regulatory documents caution that some types of yeast, particularly Candida glabrata and Candida krusei, have been known to show reduced susceptibility or resistance to the drug, which may affect the clinical outcome.

Q: Can Флюкостат be used during pregnancy or breastfeeding?

A: Official information states that its use during pregnancy is limited to conditions where the potential benefit is judged to outweigh the potential fetal risk. For breastfeeding, use is generally not recommended for repeated or high-dose regimens.

Q: What are the rare but serious side effects of Флюкостат?

A: Rare but serious documented adverse effects include severe liver toxicity (hepatotoxicity), severe skin reactions, and specific cardiac rhythm disturbances (QT prolongation). Due to the potential for these risks, regulatory documents advise that close monitoring be performed.

Q: Does Флюкостат cause changes in mood or sleep?

A: Official adverse reaction reports do not list changes in mood. However, they do list insomnia (difficulty sleeping) and dizziness as uncommon side effects that have been documented with the use of fluconazole.

Q: How is the dose of Флюкостат determined for different conditions?

A: Dosing is officially indication-specific, meaning the prescribed amount depends on the type and location of the fungal infection being treated (such as vaginal, esophageal, or systemic candidiasis). The dose is also adjusted based on patient factors like age, weight, and kidney function, as detailed in regulatory guidelines.

Q: Can Флюкостат be crushed or chewed?

A: The ability to alter solid forms (capsules or tablets) depends on the specific product formulation. If swallowing is difficult, some formulations may be officially approved for crushing or cutting. Patients are advised to follow the specific administration instructions provided with the dispensed product.

Q: What are the most common things people take Флюкостат for?

A: The most common officially indicated uses for fluconazole include the treatment of vulvovaginal candidiasis (vaginal yeast infection) and mucocutaneous candidiasis, which involves infections of the mucous membranes, such as oral thrush or infection of the esophagus.

Q: Can Флюкостат be used for preventive reasons?

A: Yes, fluconazole is officially indicated for use as prophylaxis, which means it is used to prevent fungal infections. This is typically done in certain high-risk patient populations, such as those undergoing bone marrow transplantation who are susceptible to severe fungal infections.

Q: How quickly does Флюкостат start working after taking it?

A: The drug is rapidly and almost completely absorbed when taken by mouth, with peak concentrations in the bloodstream typically occurring within 1 to 2 hours. The time until symptoms resolve for an infection can vary significantly depending on the type and severity of the condition being treated.

Q: Can Флюкостат affect blood sugar levels?

A: Official drug interaction information indicates that fluconazole may increase the effects of some oral anti-diabetic medications (sulfonylureas) by altering their metabolism. This interaction could potentially increase the risk of low blood sugar (hypoglycemia), requiring close monitoring of blood sugar levels.

Q: Is there a generic version of Флюкостат?

A: Yes, Флюкостат is a specific brand name for the active drug, which is fluconazole. Fluconazole is widely available in generic form from various pharmaceutical manufacturers worldwide.

Q: Does taking Флюкостат cause hair loss?

A: Official regulatory documents have reported hair loss (alopecia) as a possible side effect associated with the use of fluconazole.

Q: Does Флюкостат lose its effectiveness over time?

A: The drug itself, when stored properly, maintains its labeled potency. However, official documents address the growing concern of acquired fungal resistance. This means that some fungal organisms may become less susceptible to the drug during or after prolonged treatment, which can lead to reduced clinical effect.

Q: Why is Флюкостат sometimes listed under different brand names?

A: Fluconazole is the official generic name for the active chemical ingredient. It is a common practice for pharmaceutical companies globally to market the same generic drug under various distinct brand names (such as Diflucan or Флюкостат) in different regions.

Q: Does Флюкостат interact with herbal supplements?

A: Official drug labels warn of interactions with medicines metabolized by certain liver enzymes (CYP2C9 and CYP3A4). While specific herbal supplements may not be listed, any supplement known to affect these same liver enzymes could potentially interact with fluconazole, which warrants caution.

Q: Is Флюкостат safe to use in older people (elderly)?

A: The drug is approved for use in elderly patients. However, since fluconazole is primarily cleared by the kidneys, official dosage adjustments may be required for older patients who have reduced kidney function, which is a factor detailed in official guidelines.

Q: Why might a patient need a blood test while taking Флюкостат?

A: Blood tests are officially recommended to monitor liver function. Because fluconazole carries a risk of rare but serious liver toxicity, regulatory documents advise careful monitoring of liver enzyme levels, especially during long-term treatment or in patients with pre-existing liver conditions.

Q: Can Флюкостат cause skin rashes other than an allergic reaction?

A: Yes, a general skin rash is listed as a common side effect of fluconazole. This is distinct from the rare, severe skin reactions or anaphylaxis, which are described as requiring immediate medical attention.

Q: Can taking Флюкостат change the color of urine or stools?

A: The drug itself is not described as directly changing the color of urine or stools. However, official patient information warns that symptoms such as dark-colored urine and light-colored stools are signs of rare, serious liver problems that are an adverse event associated with fluconazole.

Q: How long does Флюкостат stay in the body?

A: The active substance fluconazole has a relatively long elimination half-life, meaning it remains in the body for an extended period. The average half-life in healthy adults is described in regulatory documents as approximately 30 hours, which supports its once-daily dosing.

Q: Are there specific times of day that Флюкостат should be taken?

A: The drug is officially prescribed to be taken once daily. While the administration may be done with or without food, taking the dose around the same time each day is generally considered helpful for maintaining consistent drug levels in the body over the course of treatment.

Q: Is there any evidence for Флюкостат affecting fertility?

A: Official regulatory documents do not provide extensive details on human fertility studies. Animal studies have shown no adverse effects on male or female fertility at specific dose levels, but extrapolation of these findings to humans is always limited.

Advertisements

How should Флюкостат be stored and disposed of?

Official Storage and Disposal Requirements

Fluconazole storage conditions are specifically detailed in regulatory documents based on the dosage form to ensure drug stability.

Dosage Form Required Storage Conditions
Tablets/Dry Powder Store below 30 °C (86 °F) at Controlled Room Temperature.
IV Solution Store between 5 °C and 25 °C (41 °F and 77 °F). Protect from freezing.
Reconstituted Suspension Store between 5 °C and 30 °C (41 °F and 86 °F). Discard any unused portion after 2 weeks.

All forms of the medication must be kept in the container that it came in, with the container kept tightly closed to protect it from moisture. Fluconazole must be stored out of the reach of children, as mandated by official labeling. Disposal of unused or expired product must be done by throwing it away and following national and local regulations, including governmental guidelines for safe medicine disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Флюкостат found in:

A-Z Index: